1994
DOI: 10.1016/s0002-9378(94)70077-x
|View full text |Cite
|
Sign up to set email alerts
|

Interleukin-10 in amniotic fluid at midtrimester: Immune activation and suppression in relation to fetal growth

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

2
46
0
1

Year Published

1995
1995
2022
2022

Publication Types

Select...
9
1

Relationship

1
9

Authors

Journals

citations
Cited by 79 publications
(49 citation statements)
references
References 19 publications
2
46
0
1
Order By: Relevance
“…The lack of benefit of IL-10 treatment for fetal mass contrasts with previous experiments in rats where LPS-induced fetal growth restriction was alleviated with exogenous IL-10 supplied at similar doses (28,29). However, consistent with our findings, human clinical studies link elevated placental and amniotic IL-10 synthesis with in utero growth restriction (61).…”
Section: Discussionsupporting
confidence: 71%
“…The lack of benefit of IL-10 treatment for fetal mass contrasts with previous experiments in rats where LPS-induced fetal growth restriction was alleviated with exogenous IL-10 supplied at similar doses (28,29). However, consistent with our findings, human clinical studies link elevated placental and amniotic IL-10 synthesis with in utero growth restriction (61).…”
Section: Discussionsupporting
confidence: 71%
“…Dysregulation of anti-inflammatory mediators has also been reported in these pathologies. IL10 levels are elevated in amniotic fluid at mid-trimester in women with intrauterine growth restriction and elevated in term placenta in women with preeclampsia (Heyborne et al 1994, Rinehart et al 1999. IL10 has also been reported to be aberrantly expressed in decidual T lymphocytes in women with recurrent miscarriage (Piccinni et al 1998).…”
Section: Inflammatory Pathways In Reproductive Pathologymentioning
confidence: 99%
“…Inversely, failure to mount a local inflammatory response in early or late gestation can also lead to adverse conditions, including miscarriages. Evidence shows that impaired inflammatory response is implicated in numerous female reproductive tract pathologies including menstrual disorders (Sales & Jabbour 2003), endometriosis-associated infertility (Gupta et al 2008), recurrent miscarriage (von Wolff et al 2000, Laird et al 2003, intrauterine growth restriction (Heyborne et al 1994), preeclampsia , Rinehart et al 1999) and preterm labor (Romero et al 2006. Infertility has an estimated global prevalence of 9% with >72 million infertile women worldwide (Boivin et al 2007), whereas preterm birth and preeclampsia, the two leading causes of perinatal mortality and morbidity, have an estimated prevalence of >11% (Blencowe et al 2013) and 3-5% (Ananth et al 2013 respectively.…”
Section: Introductionmentioning
confidence: 99%